Navigation Links
PTC Therapeutics Announces Achievement of Major Milestone in Schering-Plough Hepatitis C Collaboration
Date:8/10/2009

l need and we are pleased to be on the road to provide additional treatment options for patients."

About GEMS(TM)

Gene Expression Modulation by Small-molecules (GEMS(TM)) is PTC's novel and proprietary technology platform for the identification of small-molecules that modulate post-transcriptional control mechanisms. Compounds identified through the GEMS technology target processes that act through the untranslated regions (UTRs) of messenger RNA (mRNA) molecules. PTC has successfully employed the GEMS technology in drug discovery programs in oncology, infectious diseases, cardiovascular diseases, and neuromuscular disorders with corporate partners such as Celgene, Gilead, Pfizer, and Schering-Plough.

About Hepatitis C (HCV)

Hepatitis C is inflammation of the liver caused by the hepatitis C virus. Approximately 4 million people in the U.S. are infected with hepatitis C, according to the National Institutes of Health. Additionally, the World Health Organization estimates 170 million persons are chronically infected with HCV worldwide and 3 to 4 million persons are newly infected each year. HCV is spread primarily by direct contact with human blood. At least 80% of patients with hepatitis C develop a chronic liver infection. It is the leading cause of liver failure requiring liver transplantation in both the United States and Europe. The Centers for Disease Control, or CDC, estimate that approximately 8,000 to 10,000 patients die annually in the United States from complications resulting from this infection. There are no available vaccines against HCV. The current standard of care for the treatment of HCV is a combination of two drugs, interferon and ribavirin. More than 50% of patients infected with the genotype 1 strain of HCV generally do not respond to this therapy. In addition, there are significant side effects to this therapy, which often result in dose reductions or prem
'/>"/>

SOURCE PTC Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Cell Therapeutics Second Quarter Net Loss Decreases 54%; Pixantrone NDA Submitted to the FDA for Approval
2. The Breast Cancer Therapeutics Market in Australia
3. Amicus Therapeutics Announces Second Quarter 2009 Financial Results
4. Orexigen(R) Therapeutics to Speak at Canaccord Adams Global Growth Conference
5. Nile Therapeutics, Inc. Announces Dosing of First Patient in Phase 2 Study of CD-NP for the Treatment of Acute Heart Failure
6. Nektar Therapeutics to Present at the BMO Capital Markets 9th Annual Focus on Healthcare Conference in New York City
7. Stemline Therapeutics CEO to Present at IBCs New Frontiers in Cancer Drug Development Conference
8. Cornerstone Therapeutics Announces Closing of Chiesi Transaction
9. Amicus Therapeutics Announces Second Quarter 2009 Financial Results Release Date
10. PTC Therapeutics Initiates Phase 2 Clinical Trial of PTC299 in Patients with Neurofibromatosis Type 2
11. Orexigen(R) Therapeutics Announces Full Exercise of Overallotment Option by Underwriters
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... July 11, 2014  Researchers have pioneered a ... The new technology, called Virtual Finger, allows scientists ... like neurons and synapses using the flat surface ... makes 3D imaging studies orders of magnitude more ... unprecedented level across many areas of experimental biology. ...
(Date:7/10/2014)... 2014 Understanding the need for better ... and the gap that currently exists in this area, ... industry-leading portfolio of validated ion channel and GPCR cell ... lines, as ion channels control many critical physiological functions ... creates the potential to treat a variety of human ...
(Date:7/10/2014)... EvoDerma ’s NOOME Anti-Aging Motion has been upgraded for ... a second treatment cup to help prevent and smooth skin ... thinner on the edges for a softer contact with the ... surfaces on the face, neck and décolleté. Choose to use ... such as the cheeks and neck, or opt for the ...
(Date:7/10/2014)... , July 10, 2014 /PRNewswire-iReach/ -- ... and interpretation, today announced an agreement with ... analytics for Lineagen,s NextStep Dx PLUS.  ... neurodevelopmental and neurological disorders, currently offers FirstStep ... (CMA) testing service used by healthcare providers ...
Breaking Biology Technology:Virtual Finger Enables Scientists To Navigate And Analyze 3D Images Of Complex Biological Structures 2Virtual Finger Enables Scientists To Navigate And Analyze 3D Images Of Complex Biological Structures 3Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 2Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 3Introducing a New Bonus Treatment Cup for EvoDerma’s NOOME Anti-Aging Motion 2Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 2Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 3Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 4
... DIEGO, June 4 Anadys Pharmaceuticals, Inc. (Nasdaq: ... operations on the development of ANA598, in particular a proposed ... combination with pegylated interferon-alpha and ribavirin. , ... suspend further development of ANA773 and is reducing its workforce ...
... Push of a Button , , CLEVELAND, June 4 ... the patented probiotic strain Ganeden BC30 (R), today announced a ... beverage using PowerCap(R) technology, the innovative bottle cap dispensing system. ... with the press of a button, creating a new category ...
... Roche at 69th Scientific Sessions , , SAN ... VIAP ), a biotechnology company focused on the ... metabolic disease, announced today that preclinical data related to ... presented in a poster presentation at the 69th Scientific ...
Cached Biology Technology:Anadys Pharmaceuticals, Inc. Announces Strategic Restructuring to Focus Operations on Continuing the Advancement of ANA598 2Anadys Pharmaceuticals, Inc. Announces Strategic Restructuring to Focus Operations on Continuing the Advancement of ANA598 3Anadys Pharmaceuticals, Inc. Announces Strategic Restructuring to Focus Operations on Continuing the Advancement of ANA598 4Anadys Pharmaceuticals, Inc. Announces Strategic Restructuring to Focus Operations on Continuing the Advancement of ANA598 5Ganeden Biotech, Liquid Health Labs Unveil New Drink Technology 2Ganeden Biotech, Liquid Health Labs Unveil New Drink Technology 3VIA Pharmaceuticals' DGAT1 Inhibitors Featured in American Diabetes Association Poster Presentation 2VIA Pharmaceuticals' DGAT1 Inhibitors Featured in American Diabetes Association Poster Presentation 3VIA Pharmaceuticals' DGAT1 Inhibitors Featured in American Diabetes Association Poster Presentation 4
(Date:7/10/2014)... , June 27, 2014  The American Academy ... Institute of Standards and Technology (NIST) and the ... academic research and forensic science expert members to ... is an element of the NIST,s Organization of ... among the first appointments made to the new ...
(Date:7/10/2014)... 30, 2014  Aware, Inc. (NASDAQ: AWRE ... previously announced on June 26, 2014 that its Board ... $1.75 per share, or approximately $40 million in total.  ... 2014 and a payment date of July 24, 2014.  ... had set an ex-dividend date for this special cash ...
(Date:7/10/2014)... 2014  Unisys Corporation,s (NYSE: UIS ) subsidiary ... today announced that it has been selected by the Dutch ... new Basic Provision Biometrics solution for penitentiaries across ... contract with a solution based on its open standards-based ... the contract is up to seven years, with the new ...
Breaking Biology News(10 mins):Ten Members of the American Academy of Forensic Sciences Appointed to Forensic Science Standards Board (FSSB) 2Ten Members of the American Academy of Forensic Sciences Appointed to Forensic Science Standards Board (FSSB) 3NASDAQ Sets Ex-Dividend Date for Aware, Inc.'s Special Cash Dividend of $1.75 Per Share 2Unisys Delivers New Basic Provision Biometrics Solution to Dutch Custodial Institutions Service 2Unisys Delivers New Basic Provision Biometrics Solution to Dutch Custodial Institutions Service 3
... first time, UK scientists have reported direct evidence that taking ... of cancer. The results were reported at the 35th ... Milan, Italy. The link between smoking and cancer has ... the Cancer Research UK Institute of Cancer Studies, Birmingham, who ...
... cancer patients seem to live longer and experience delays in ... molecule called MET is added to treatment with erlotinib, the ... David Spigel, Director of lung cancer research for the Sarah ... at the 35th Congress of the European Society for Medical ...
... Researchers at the University of Illinois at Chicago College of ... drug resistance is ramped up in unusual types of breast ... study is published in the Oct. 8 issue of the ... a paper of the week. Approximately 70 percent of ...
Cached Biology News:Study reveals cancer-linked epigenetic effects of smoking 2New targeted therapy adds benefit to erlotinib in some patients with advanced lung cancer 2Clue to unusual drug-resistant breast cancers found 2
ANTI S. ENT TOX BC2D...
... Anti-Major DNA-binding protein(DBP). Protein ... NP_001343 ELISA titre using ... Suggested conditions for Western Blot: ... buffer, and HRP conjugated anti-Rabbit IgG should ...
Collected from sexually mature, mixed sex, mixed breed guinea pigs. Pricing: $120/unit for 1 - 10 units...
SEQUENASE PCR PRODUCT PRE-SEQU, 1 EA. Category: SEQUENASE....
Biology Products: